Results 31 to 40 of about 2,912,203 (303)

Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up [PDF]

, 2015
Objective. Atrophic gastritis (AG) is a risk condition for gastric cancer and type I gastric carcinoids. Recent studies assessing the overall risk of gastric cancer and carcinoids in AG at long-term follow up are lacking.
Annibale, Bruno, Corleto, Vito Domenico, DI GIULIO, Emilio, Esposito, Gianluca, Lahner, Edith, Pilozzi, Emanuela, Purchiaroni, Flaminia   +6 more
core   +2 more sources

Primary Carcinoid Tumor of the Testis: Case Report

Urology Case Reports, 2015
Carcinoid tumors conform less than 1% of all testicular tumors and most of them are neuroendocrine tumors which are primarily seen in testes. They are in the form of testicular metastasis from other organs. Carcinoid tumors may occur from differentiation
Mustafa Suat Bolat, Ekrem Akdeniz, Fatma Saltık, Necmettin Sahinkaya, Caner Moral   +4 more
doaj   +1 more source

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

Annals of Oncology, 2015
BACKGROUND Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management.
M. Caplin, E. Baudin, P. Ferolla, Filosso Pl, M. Garcı́a-Yuste, E. Lim, K. Öberg, G. Pelosi, A. Perren, R. E. Rossi, R. Rossi, W. Travis   +11 more
semanticscholar   +1 more source

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. [PDF]

, 2016
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Degesys, Aiste, Jenkins, John, Oronsky, Bryan, Peterson, P Gabriel, Quinn, Mary, Reid, Tony R, Schmitz, Bruno, Scicinski, Jan   +11 more
core   +4 more sources

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome

Case Reports in Gastroenterology, 2018
Neuroendocrine neoplasms (NENs) are a diverse group of tumors arising throughout the body with a common origin from neuroendocrine cells. Well-differentiated NENs, also known as neuroendocrine tumors (NETs), are generally indolent and are often found ...
Oluwaseun Shogbesan, Abdullateef Abdulkareem, Binu Pappachen, John Altomare   +3 more
doaj   +1 more source

Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors

Clinical Cancer Research, 2018
Purpose: Pulmonary carcinoid tumors account for up to 5% of all lung malignancies in adults, comprise 30% of all carcinoid malignancies, and are defined histologically as typical carcinoid (TC) and atypical carcinoid (AC) tumors.
M. Asiedu, C. Thomas, Jie Dong, S. Schulte, Prasidda Khadka, Zhifu Sun, F. Kosari, J. Jen, J. Molina, G. Vasmatzis, R. Kuang, M. Aubry, Ping Yang, D. Wigle   +13 more
semanticscholar   +1 more source

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors [PDF]

, 2018
Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
Baldelli, Roberto, Campana, Davide, Di Giacinto, Paola, Isidori, Andrea, Lania, Andrea, Lenzi, Andrea, Rizza, Laura, Rota, Francesca, Zuppi, Paolo   +8 more
core   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones [PDF]

, 1997
Chromogranin A (CgA) is gaining acceptance as a serum marker of neuroendocrine tumors. Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its sensitivity to detect small tumors, and its clinical ...
Bouillon, R. (Roger), Coopmans, W., Herder, W.W. (Wouter) de, Krenning, E.P. (Eric), Kwekkeboom, D.J. (Dirk Jan), Lamberts, S.W.J. (Steven), Lindemans, J. (Jan), Nobels, F.R.E. (Frank), Schoenmakers, C.H.H. (Christian)   +8 more
core   +13 more sources

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM, Auernhammer CJ, Boulay A, Boulay A, Bousquet C, Burkhard Göke, Cao C, Christoph J. Auernhammer, Enrico N. De Toni, Faivre S, Gerald Spöttl, Grewe M, Heinrich H.D. Meyer, Hosoi H, Jeng YJ, Jennifer Meinecke, Kathrin Zitzmann, Kawamata S, Kirchner GI, Luo J, O?Reilly KE, Oberg K, Ramage JK, Sawyers CL, Shah T, Shaw RJ, Stephan Brand, Sun SY, Vignot S, von Wichert G, Wang L, Wanner K, Wendel HG, Wullschleger S, Yao JC, Yee KW   +35 more
core   +1 more source